Anzeige
Mehr »
Dienstag, 02.09.2025 - Börsentäglich über 12.000 News
Milliardenmarkt Multiple Sklerose: Neue Therapieform könnte alles verändern!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 855526 | ISIN: JP3160400002 | Ticker-Symbol: EII
Tradegate
02.09.25 | 18:09
27,000 Euro
-1,93 % -0,530
Branche
Pharma
Aktienmarkt
NIKKEI-225
1-Jahres-Chart
EISAI CO LTD Chart 1 Jahr
5-Tage-Chart
EISAI CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
27,00027,25021:31
27,02027,29021:31

Aktuelle News zur EISAI Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
12:46Alzheimer's Therapy Is Coming to the Home With FDA Approval of Injectable Eisai, Biogen Drug5
MoEisai's Leqembi unlocks at-home dosing with FDA autoinjector approval6
MoFDA approves Eisai and Biogen's Leqembi Iqlik BLA for early Alzheimer's7
MoEisai: FDA Approves LEQEMBI IQLIK For Maintenance Dosing In Treatment Of Early Alzheimer's275WESTON (dpa-AFX) - Eisai and Biogen (BIIB) announced that the FDA has approved the Biologics License Application for once weekly lecanemab-irmb subcutaneous injection, or LEQEMBI IQLIK, for...
► Artikel lesen
EISAI Aktie jetzt für 0€ handeln
MoEisai-Aktie gewinnt 4,07 Prozent (27,33 €)222Am Aktienmarkt liegt die Eisai-Aktie derzeit im Plus. Zuletzt zahlten Investoren für das Papier 27,33 Euro. Freuen können sich gegenwärtig die Aktionäre von Eisai: Die Aktie weist zur Stunde einen Preisanstieg...
► Artikel lesen
MoEisai: FDA Approves LEQEMBI® IQLIKTM (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease206TOKYO and CAMBRIDGE, Mass., Sept 1, 2025 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO:...
► Artikel lesen
SaBiogen/Eisai: Marktstart für Alzheimer-Mittel Lecanemab in Deutschland834BERLIN (dpa-AFX) - Der zur Alzheimer-Therapie zugelassene Antikörper Lecanemab kommt am 1. September in Deutschland offiziell auf den Markt. Österreich und Deutschland seien die ersten EU-Länder, in...
► Artikel lesen
FrFDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment5
FrEisai Inc.: FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease2.060LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless...
► Artikel lesen
FrEisai: Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma262TOKYO, Aug 29, 2025 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has received orphan drug designation for anticancer agent the EZH2*1 inhibitor...
► Artikel lesen
25.08.Eisai: Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab)236TOKYO and CAMBRIDGE, Mass., Aug 25, 2025 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts...
► Artikel lesen
25.08.BioArctic, Eisai Unveil Leqembi Therapy For Alzheimer's Treatment In Austria, Germany5
18.08.Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China344TOKYO, Aug 18, 2025 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the in-house discovered and developed orexin receptor antagonist DAYVIGO(R)(brand...
► Artikel lesen
12.08.Biogen/Eisai's Alzheimer's drug Leqembi shows continued benefit over four years30
05.08.Eisai Q1 Pre-tax Profit Surges 40.3%368TOKYO (dpa-AFX) - Eisai Co., Ltd. (ESALY.PK) Tuesday reported profit before tax of 22.404 billion yen for the first quarter, 40.3% higher than 15.969 billion yen in the same quarter a year ago...
► Artikel lesen
31.07.Eisai: Revenue of LEQEMBI(R) (Preliminary Basis)451TOKYO, July 31, 2025 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the global revenue(pre-audit basis) of the anti-amyloid-beta protofibril...
► Artikel lesen
31.07.Eisai: Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC509TOKYO and CAMBRIDGE, Mass., July 31, 2025 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai")and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO:...
► Artikel lesen
31.07.Eisai: New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease503Lecanemab subcutaneous autoinjector has the potential to become a new expanded treatment option for patients with early Alzheimer's disease, their care partners and healthcare professionals, with results...
► Artikel lesen
31.07.Eisai: Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025529TOKYO and CAMBRIDGE, Mass., July 31, 2025 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito,"Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts...
► Artikel lesen
30.07.Eisai And Biogen Say Four Years Of Leqembi Helps In Slowing Down Alzheimer's Disease Progression508WESTON (dpa-AFX) - Eisai Co., Ltd. and Biogen Inc. (BIIB) Wednesday said results from Phase 3 Clarity AD study showed that continuous treatment with Leqembi helped in slowing down the progression...
► Artikel lesen
Weiter >>
115 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,4